Agilent and the Florey Institute of Neuroscience and Mental Health are working together to help scientists gain a better understanding of neurodegenerative conditions such as Parkinson’s, Alzheimer’s and motor neuron disease.
The Florey Institute, based in Melbourne, Australia, is one of the world’s largest brain research centers and, working with Agilent, will develop techniques to detect and measure trace metals in proteins. The ability to monitor a set of metalloproteins has the potential to lead to significant advances in the understanding of disease mechanisms, as well as normal biological processes.
Unlocking the role of metalloproteins will provide a more complete picture of what goes wrong during disease processes. This understanding should create new opportunities to develop therapies that target specific metalloprotein dysfunction.
For more information go to: